down arrow

Zhejiang Conba Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001H86
  • SHG: 600572
CNY
4.32
-0.06 (-1.37%)

Sep 22

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Zhejiang Conba Pharmaceutical Co., Ltd.

Why is Zhejiang Conba Pharmaceutical Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 8.79%
  • The company has been able to generate a Return on Capital Employed (avg) of 8.79% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 2.97% and Operating profit at 1.76% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 15.16% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 2.97% and Operating profit at 1.76% over the last 5 years
4
Positive results in Jun 26
  • INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
  • RAW MATERIAL COST(Y) Fallen by -8.48% (YoY)
  • INVENTORY TURNOVER RATIO(HY) Highest at 2.84 times
5
With ROE of 6.70%, it has a fair valuation with a 1.36 Price to Book Value
  • Over the past year, while the stock has generated a return of -1.59%, its profits have fallen by -16.6%
  • At the current price, the company has a high dividend yield of 3.9
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Zhejiang Conba Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Conba Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Zhejiang Conba Pharmaceutical Co., Ltd.
-1.59%
-0.75
27.30%
China Shanghai Composite
3.23%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
2.97%
EBIT Growth (5y)
1.76%
EBIT to Interest (avg)
30.10
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.85
Tax Ratio
28.07%
Dividend Payout Ratio
80.13%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.73%
ROE (avg)
15.16%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.36
EV to EBIT
18.50
EV to EBITDA
12.14
EV to Capital Employed
1.39
EV to Sales
1.40
PEG Ratio
NA
Dividend Yield
3.90%
ROCE (Latest)
7.51%
ROE (Latest)
6.70%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -8.48% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.84 times

OPERATING PROFIT MARGIN(Q)

Highest at 18.16 %

PRE-TAX PROFIT(Q)

At CNY 253.58 MM has Grown at 77.28%

NET PROFIT(Q)

Highest at CNY 218.26 MM

-1What is not working for the Company
CASH AND EQV(HY)

Lowest at CNY 1,761 MM

Here's what is working for Zhejiang Conba Pharmaceutical Co., Ltd.

Operating Profit Margin
Highest at 18.16 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
At CNY 253.58 MM has Grown at 77.28%
over average net sales of the previous four periods of CNY 143.04 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 218.26 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit
At CNY 218.26 MM has Grown at 86.54%
over average net sales of the previous four periods of CNY 117 MM
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Inventory Turnover Ratio
Highest at 2.84 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -8.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Conba Pharmaceutical Co., Ltd.

Cash and Eqv
Lowest at CNY 1,761 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Footer loading